Side effects include pale skin, troubled breathing, unusual bleeding or bruising, unusual tiredness or weakness, black, tarry stools, chest pain, chills, cough, fever, painful or difficult urination, shortness of breath, sore throat, sores, ulcers, or white spots on lips or in mouth, swollen glands, increase in bowel movements, loose stools, soft stools.
Raltitrexed (brand name Tomudex®) is a chemotherapy drug manufactured AstraZeneca Company, is an antimetabolite used in chemotherapy. It is an inhibitor of thymidylate synthase.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Raltitrexed. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Raltitrexed. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Raltitrexed. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Raltitrexed. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Raltitrexed. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Raltitrexed. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Raltitrexed. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Raltitrexed. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Raltitrexed. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Raltitrexed. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Raltitrexed. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Raltitrexed. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Raltitrexed. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Raltitrexed. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Raltitrexed. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Raltitrexed. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Raltitrexed. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Raltitrexed. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Raltitrexed. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Raltitrexed. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Raltitrexed. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Raltitrexed. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Raltitrexed. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Raltitrexed. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Raltitrexed. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Raltitrexed. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Raltitrexed. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Raltitrexed. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Raltitrexed. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Raltitrexed. |
| Cladribine | Raltitrexed may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Raltitrexed. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Raltitrexed. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Raltitrexed. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Raltitrexed. |
| Mitomycin | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Mitomycin. |
| Bexarotene | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Bexarotene. |
| Vindesine | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Vindesine. |
| Floxuridine | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Floxuridine. |
| Indomethacin | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Indomethacin. |
| Tioguanine | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Tioguanine. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Vinorelbine. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Dexrazoxane. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Beclomethasone dipropionate. |
| Sorafenib | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Sorafenib. |
| Streptozocin | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Streptozocin. |
| Trifluridine | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Trifluridine. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Gemcitabine. |
| Betamethasone | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Betamethasone. |
| Teniposide | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Teniposide. |
| Epirubicin | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Epirubicin. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Chloramphenicol. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Lenalidomide. |
| Altretamine | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Altretamine. |
| Zidovudine | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Zidovudine. |
| Cisplatin | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Cisplatin. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Oxaliplatin. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Cyclophosphamide. |
| Vincristine | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Vincristine. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Fluorouracil. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Propylthiouracil. |
| Pentostatin | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Pentostatin. |
| Methotrexate | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Methotrexate. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Carbamazepine. |
| Vinblastine | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Vinblastine. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Fluticasone propionate. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Fluocinolone acetonide. |
| Linezolid | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Linezolid. |
| Imatinib | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Imatinib. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Triamcinolone. |
| Clofarabine | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Clofarabine. |
| Prednisone | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Prednisone. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Pemetrexed. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Fludrocortisone. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Mycophenolate mofetil. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Daunorubicin. |
| Irinotecan | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Irinotecan. |
| Methimazole | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Methimazole. |
| Etoposide | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Etoposide. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Sulfasalazine. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Dacarbazine. |
| Temozolomide | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Temozolomide. |
| Penicillamine | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Penicillamine. |
| Prednisolone | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Prednisolone. |
| Sirolimus | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Sirolimus. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Mechlorethamine. |
| Azacitidine | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Azacitidine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Carboplatin. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Methylprednisolone. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Dactinomycin. |
| Cytarabine | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Cytarabine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Azathioprine. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Doxorubicin. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Hydroxyurea. |
| Busulfan | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Busulfan. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Mycophenolic acid. |
| Topotecan | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Topotecan. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Mercaptopurine. |
| Thalidomide | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Thalidomide. |
| Melphalan | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Melphalan. |